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Abstract
This paper summarizes the Part 3 of the proceedings of the 8th International Conference on Management and
Rehabilitation of Chronic Respiratory Failure, held in Pescara, Italy, on 7 and 8 May, 2015. It summarizes the
contributions from numerous experts in the field of chronic respiratory disease and chronic respiratory failure. The
outline follows the temporal sequence of presentations.
This paper (Part 3) presents a section regarding Moving Across the Spectrum of Care for Long-Term Ventilation (Moving
Across the Spectrum of Care for Long-Term Ventilation, New Indications for Non-Invasive Ventilation, Elective Ventilation
in Respiratory Failure - Can you Prevent ICU Care in Patients with COPD?, Weaning in Long-Term Acute Care Hospitals
in the United States, The Difficult-to-Wean Patient: Comprehensive management, Telemonitoring in Ventilator-Dependent
Patients, Ethics and Palliative Care in Critically-Ill Respiratory Patients, and Ethics and Palliative Care in Ventilator-Dependent
Patients).
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Background
This paper summarizes the Part 3 of the proceedings of the
8th International Conference on Management and Rehabili-
tation of Chronic Respiratory Failure, held in Pescara, Italy
on 7 and 8 May, 2015. It summarizes the contributions
from numerous experts in the field of chronic respiratory
disease and chronic respiratory failure. The outline follows
the temporal sequence of presentations.
Moving across the spectrum of care for long-term
ventilation
Rationale
As technology advances, therapeutic options for individuals
with chronic respiratory failure requiring short- and long-
term ventilator support increase. This section will review
old and new indications for ventilator therapy, implementa-
tion and feasibility of these types of complex interventions,
potential methods to improve their applicability and safety,
and economic issues resulting from their use.
Moving across the spectrum of long term ventilation
(Roger Goldstein)
References to mechanical ventilation are found in the
writings of Hippocrates (460–375 BC) and Paracelsus
(1493–1541). However, since the 20th century, long term
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mechanical ventilation (LTMV) has become important in
the management of two overlapping groups of patients;
those who have recovered from an acute episode of
respiratory failure but who require ongoing ventilatory sup-
port despite being clinically stable and those who require
ventilation electively to avoid the requirement for urgent
ventilation. Added to the above, is the increased awareness
of the value of a rehabilitative focus, to enhance function
and improve autonomy of the ventilator assisted individual
(VAI) in a non ICU environment.
Mandatory ventilation
Patients receiving mandatory ventilation in the Intensive
Care Unit (ICU) find themselves in an environment in
which, understandably, the attending clinical team is
focused on those with acute clinical issues. Their mobility
is confined to the length of their ventilator tubing. Subse-
quent management outside the ICU will depend on the
availability of resources such as a chronic assisted ventila-
tor care unit, a long term acute care unit or a skilled nurs-
ing facility. The resource utilization is inversely related to
the level of patient independence (Fig. 1) [1].
With the addition of rehabilitation many VAI are able to
leave the ICU for an assisted living facility or even better,
to go home, provided they have access to technical and
clinical support services. Preparation for the relocation
should begin in the ICU, as outlined in Table 1.
The availability of physical rehabilitation in the ICU has
a positive influence on muscle function, independence
and time to wean (Table 2) [2].
Elective ventilation
In contrast, the journey of elective ventilation often begins
and ends at home. It hinges on the prompt initiation of
elective ventilation for those whose conditions are pro-
gressing to cardio-respiratory failure. Good clinical and
laboratory monitoring is important as the onset of respira-
tory failure may first be identified through a deterioration
of nocturnal blood gases. Progression may include brief
exacerbations with respiratory failure requiring ICU man-
agement and relatively easy weaning. As with mandatory
ventilation, it is necessary to have access to home respira-
tory care services as well as scheduled monitoring after
the initiation of ventilator support. The following example
illustrates the relevance of monitoring in those likely to
develop respiratory failure.
Case example
A 45 year-old woman with thoracic restriction developed
gradually progressive dyspnea on exertion. Her vital cap-
acity was 43 % predicted, her total lung capacity was 44 %
predicted and her forced expired volume in one second to
forced vital capacity was 90 %. Arterial blood gases taken
on room air showed her to have: pH 7.39, PaCO2
46 mmHg, PaO2 78 mmHg, SaO2 95 %. After an episode
Fig. 1 Potential sites of care for patients requiring PMV. Sites toward the bottom of the figure have fewer medical resources and lower costs but
allow greater patient independence and a higher quality of life. PMV, prolonged mechanical ventilation
Table 1 Beginning rehabilitation in the ICU
• Change ventilator to a home friendly, portable, simple machine
• Change the tracheostomy tube to allow speech
• Teach the patient and family airway patency (suctioning) and manual
ventilation
• Maximize mobilization (including outings)
• Introduce assistive technology for communication
• Assess swallowing
• Maximize nutrition
• Prepare to relocate
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of pneumonia a two channel overnight recording showed
satisfactory oxygenation, mild nocturnal hypercapnia with
periodic (likely REM related) worsening of gas exchange
(Fig. 2a). She began to feel unwell over the next few
months and on repeat evaluation after 6 months (Fig. 2b)
she was noted to have marked hypercapnia. Bi-level posi-
tive airway pressure ventilation was initiated electively
(Fig. 2c) and her clinical state as well as her blood gases
stabilized. She remains stable on nocturnal non- invasive
positive pressure ventilation.
Prevalence of HMV
The prevalence of home ventilation is influenced by the
increasing incidence of the underlying disorders, the
increased knowledge of the healthcare providers (HCP)
regarding the option of being safely ventilated outside of
the ICU and the guidelines and recommendations of pro-
fessional societies regarding LTMV [3]. It is also influ-
enced by the attitudes and preferences of the patient and
family as well as the availability of formal and informal
(caregiver) support services. In Europe (Fig. 3) [4] the
prevalence of HMV varies widely (France 17/100,000 to
Poland 0.1 per 100,000), as does the distribution of dis-
eases requiring ventilatory support (thoracic cage disor-
ders, neuromuscular disorders and airway disorders).
If the patient is unable to return home immediately, a
chronic assisted ventilatory care (CAVC) unit will provide
a safe, non-acute care environment with a rehabilitative
focus, to optimize health related quality of life and pro-
mote autonomy. The CAVC unit requires a multi-
dimensional continuum of services, by an interdisciplinary
team trained both in ventilator management and rehabili-
tation. The preferred patient is medically stable, mentally
alert, understands that ventilatory assistance is long term,
is prepared to participate in comprehensive training and
will relocate with appropriate supports. In order for a pa-
tient to return home, it must be safe and have the required
utilities as well as trained care givers. The availability of
home health care, technical support and organized follow-
up is critical.
Ventilator-assisted individuals’ perspectives
User perspectives [5] suggest that irrespective of ventila-
tion being elective or mandatory, the most difficult
period for coping is the initial 3 months after returning
home. When asked to give their experience of LTMV,
ventilator-assisted individuals voiced both positive and
negative experiences regarding mobility, symptoms,
equipment concerns and social implications. Disappoint-
ingly, not all users felt that they had made an informed
choice when they started ventilation or when it became
permanent.
Ventilator-assisted individuals (VAIs) have noted the
relevance of both physical and psychological adjustments
to being ventilated [6]. They describe the positive impact
that their physicians’ confidence in the effectiveness of
LTV has on them as well as the importance of the opinion
of other VAIs. The adjustment to LTMV is more difficult
when it is initiated in the ICU especially if impaired verbal
communication limits their decision to initiate ventilation.
The following quotes are illustrative of some of the experi-
ences of the ventilator-assisted individuals:
Adjustment quotes
“As I became stronger I thought what is so different
about my care that I could not learn?”
“Lots to do with cleaning equipment and tracking
supplies but I do it as part of my daily routine and its
easier.”
Table 2 Effects of physical training (6 weeks) for patients ventilated > 14 days (n = 39)
Baseline Sixth week
Control group Treatment group Control group Treatment group
Shoulder flexors, kg 2.0 3.2 0.9 4.5a
Elbow flexors, kg 4.5 4.3 1.1 7.3a
Knee extensors, kg 4.1 4.1 1.8 7.3a
PImax -cmH2O 38.0 46.0 30.0 60.0
a
PEmax cmH2O 42.0 45.0 35.0 62.0
a
FIM
ADL 6.0 6.0 6.0 13.0a
Mobility 5.0 5.0 5.0 9.0a
Executive 19.0 20.0 13.0 24.0a
Total 33.0 34.0 26.0 49.0a
8 treatment and 3 control subjects reached 12 h of ventilator free time
ap < 0.05 compared with control
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Fig. 2 a-c Sleep study, two channel recordings. a) Initial study in a 45 year-old woman with thoracic restriction showing satisfactory oxygenation
and mild nocturnal hypercapnia. b) Repeat evaluation after 6 months showing respiratory failure. c) After elective initiation of Bi-level Positive
Airway Pressure Ventilation, showing stabilization of nighttime gas exchange which was associated in an improved clinical state
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“I wish I would have started with the ventilator earlier as
I might have avoided getting so sick and the ICU
experience.”
Satisfaction and success quotes
“My energy was back, I was renewed, I felt
wonderful. It was noisy as the air escaped with
every breath but that didn’t bother me as I was so
glad to have this thing to help me breathe.”
“It just gave me so much more energy to work through
the day. I figured what the heck, why struggle when I
don’t have to.”
Their overall recommendations included:
1. Enhancing quality of life through improvements
in healthcare funding, healthcare professional
education and ventilator equipment design.
2. Reducing barriers through improved public
education, access to government programs and
community accessibility.
3. Educating prospective users about LTV, accepting
it as soon as it is indicated and being aware of
the personal responsibilities involved.
4. Engaging HCP to support the users’ decision for
HMV, improving HCP education regarding HMV
5. Partnering with an experienced VAI whose expertise
can be of great value in establishing optimum care.
Caregiver burden
Separate from the paid caregivers, informal caregivers,
usually family members, are essential to the development
of an environment that enables the ventilator-assisted in-
dividual to live safely at home. These informal caregivers
often underestimate the care burden involved, which is es-
pecially high when that individual also has neuromuscular
disease (NMD). Semi-structured caregiver interviews [7]
of those looking after patients with NMD highlighted their
sense of duty and their huge commitment. However care-
giver burnout was evident and the need for professional
support, especially in the initial weeks of their loved ones
returning home, was evident.
The following quotes are illustrative of some of the
issues that the caregivers face:
Restriction in day-to-day life
“I am a prisoner in my own home, at my own will.
Although I don’t regret it, this is the way I feel.”
“But it’s being deprived of my life, my family, my
future, of my expectations for my retirement, of
everything – it’s gone.”
Fig. 3 HMV in Europe by Category: Percentage of users in each disease category by country: From [4] with permission of the European Respiratory Society.
neuromuscular; thoracic cage disorders; lung and airway disorders. HMV was defined as a period of ventilation≥ 3 months outside of an acute
care hospital
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Physical and emotional burden
“There are things that are hard for me to help him as
my hands get stiff. I have a herniated disc too. I think
it is all from him.”
“So even at night when you sleep, you are sleeping
with one eye open. I’m a very light sleeper and I’ve
been having a problem for many years because of a
lack of sleep.”
“I have depression and I feel sad most of the time.
Sometimes I hate my life.”
Training and education
“It was very hard to come home the first time after
the hospital. Even though we got trained you don’t
know what to expect so it was very difficult.”
“It’s not enough to only teach the medical things, you
need to know what to expect in the long run. Knowing
about the disease really helps.”
“It’s quite overwhelming in the beginning.”
Tele-medicine follow-up
Key points that contribute to caregiver success are sum-
marized in Table 3. Regular pre-scheduled follow-up, the
ability for VAI initiated medical support and respite care
for the ventilator-assisted individual or caregiver, are
especially important.
The frequency and complexity of follow up is de-
termined by both medical and social factors. It will
vary among individuals and in the same individual at
different points in time. The arrival of modern tele-
medicine technology has resulted in more frequent
home based rather than the institutional follow-up.
For example, video-conferencing is achievable with a
personal laptop computer, linked to healthcare pro-
fessionals through videoconferencing software and
high speed internet. Regular sessions can be sched-
uled for the VAIs convenience. The patient, family,
caregiver and health team can all be present as can
a pulmonologist and a community care access case
manager. This approach has the advantage of enabling
more frequent follow-up at home and broad health team
access. It is also less expensive than home visits.
Summary
Although the spectrum of long term ventilation begins
with either mandatory or elective ventilation, the ideal
destination is home or if this is not possible a safe non
acute care facility with a multidisciplinary team trained in
both LTMV and rehabilitation. User perspectives emphasize
that the most difficult period of coping is the first few
months after returning home, when both physical and psy-
chological adjustments are necessary. Caregiver burden is
substantial and under-recognized both by the healthcare
team and by the caregivers when they make their initial
commitment to accept a ventilator-assisted individual at
home. Access to home healthcare and technical services is
critical to successful home ventilation. Telemedicine tech-
nology using personal computer video-conferencing soft-
ware has enabled more frequent, less expensive follow-up
with improved access by the patient and the caregiver to
healthcare professionals.
New indications for non-invasive ventilation (Nicolino
Ambrosino)
Key points
 The use of non invasive ventilation (NIV) is an
option in acute hypercapnic respiratory failure,
cardiogenic pulmonary oedema, acute respiratory
distress syndrome (ARDS), community-acquired
pneumonia, and weaning failure
 Evidence supports NIV during complicated
bronchoscopy, some cases of transoesophageal
echocardiography, and in some interventional
cardiology
 NIV can reduce the need for deep sedation or
general anaesthesia
 NIV should be considered with caution in severe
communicable airborne infections likely to progress
to ARDS
 The role of assisted ventilation during exercise
training is still controversial
 NIV should be applied under close monitoring, and
endotracheal intubation should be promptly
available in the case of failure.
 A trained team, careful patient selection and optimal
choice of devices, can optimize outcome of NIV
Non invasive ventilation (NIV) may be considered as one
of the most important advances in respiratory medicine
over the past 20 years, [8, 9] and is increasingly being uti-
lized world-wide [10]. A PubMed search from January 1966
to March 2015 with the term “non invasive ventilation”
Table 3 Key points for caregiver success
• Huge commitment made by family caregivers
• Caregiver burden despite formal home ventilation training
• The need to introduce post training discussion, assessment of
caregiver skills
• Increase professional supports in the initial weeks
• Increased home follow-up to recognize issues
• Closer integration between hospital and community
• Respite care for caregivers
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offers 6904 papers. The International Consensus Confer-
ence 2001 [11] defines NIV as “any form of ventilatory sup-
port applied without endotracheal intubation (ETI)”. There
is strong evidence (Level A) for the use of NIV to prevent
ETI in acute on chronic respiratory failure, acute cardio-
genic pulmonary oedema, and to facilitate extubation in
patients with acute exacerbations of chronic obstructive
pulmonary disease (COPD). Less evidence supports the use
of NIV for patients with severe acute asthma exacerbations,
post-operative or post-extubation acute respiratory failure
(ARF), pneumonia, or acute respiratory distress syndrome
(ARDS) [8, 9]. Nevertheless, many other potential applica-
tions have been proposed [12]. This review will focus on
potential new indications for NIV.
Although potentially risky, bronchoscopy may be re-
quired for some severely hypoxaemic patients [13]. In the
past, the American Thoracic Society (ATS) did not recom-
mend flexible bronchoscopy and bronchoalveolar lavage
(BAL) in such conditions when supplemental oxygen can-
not correct an arterial oxygen tension (PaO2) at least to
75 mmHg or an arterial oxygen saturation (SaO2) to 90 %
[14]. On the other hand, non-use of bronchoscopy in these
high risk patients may result in less effective, empiric treat-
ment. Until recently, when bronchoscopy wws needed in
hypoxaemic conditions, only ETI and mechanical ventila-
tion were available to provide adequate ventilation and oxy-
genation. Unfortunately, invasive mechanical ventilation is
associated with complications related to ETI, baro- or volu-
trauma, and the loss of airway defense mechanisms. NIV
has the potential to avoid these complications while ensur-
ing a similar level of ventilatory efficacy and control of
hypoxemia.
In a randomised controlled trial (RCT), mask Continu-
ous Positive Airway Pressure (CPAP) reduced the risk of
acute respiratory failure complicating bronchoscopy in
severely hypoxaemic patients [15]. Another RCT in
hypoxaemic patients showed that during bronchoscopy
NIV increased the PaO2/inspiratory oxygen fraction
(FIO2) ratio, whereas the patients randomised to only
oxygen therapy showed a worsening in oxygenation [16].
NIV during bronchoscopy is also useful in hypercapnic
COPD patients with pneumonia [17]. CPAP was able to
reverse reductions in tidal volume and respiratory flow
associated to flexible bronchoscopy in spontaneously
breathing young children [18]. In patients with acute ex-
acerbation of COPD due to community-acquired pneu-
monia, in danger of ETI and unable to clear secretions,
NIV with early therapeutic bronchoscopy was feasible,
safe and effective [19]. A recent study suggests that in
awake, critically ill patients with moderate to severe hyp-
oxaemia undergoing bronchoscopy, the application of
NIV is superior to High Flow Nasal Cannula Oxygen in
oxygenation before, during and after the procedure [20].
NIV during bronchoscopy may be performed by means
of commercial or modified oronasal or full-face masks
[21]. These reports support the use of NIV during fiber-
optic bronchoscopy especially when risks of ETI are
high, such as in immunocompromised patients. How-
ever, an expert team with skills in both endoscopy and
NIV should be available for any emergency [12]. In gen-
eral, this should be performed in ICU.
Transoesophageal echocardiography and interventional
cardiology
In orthopnoeic cardiac patients needing transoesophageal
echocardiography (TEE), NIV can reduce the need for deep
sedation or general anaesthesia. NIV allows performance of
continuous TEE examination in lightly sedated patients,
avoiding ETI and general anaesthesia. The level of evidence
is lower than in fiberoptic bronchoscopy and is more linked
to author’s experience [22]. The author of this review is not
aware of recommendations in such situations.
Recent advances in interventional techniques have made
it possible to offer minimally invasive treatment of aortic
valve stenosis to elderly or complex patients unable to
undergo standard surgical procedures due to a compro-
mised health status or severe comorbidities, such as pul-
monary diseases [22]. Furthermore, orthopnoea may make
it difficult for patients to stay supine. Our initial experience
with NIV in interventional cardiology to support patients
with severe pulmonary disease needing percutaneous
implantation of an aortic bioprosthesis for severe valve
stenosis was positive [23]. NIV reduced the need for general
anaesthesia, relieved orthopnoea and prevented post-
operative ARF [23]. As for TEE, the evidence behind this
review is based mainly on author’s experience, and a large
clinical trail would be needed to confirm this preliminary
observation.
Interventional pulmonology
Intermittent Negative Pressure Ventilation (INPV) through
a poncho-wrap may be useful in reducing apnoeas during
laser therapy under general anaesthesia, thus reducing hy-
percapnia, related acidosis, and required oxygen supple-
mentation with related explosion hazard [20]. Furthermore,
compared with spontaneous ventilation, INPV in paralysed
patients during interventional rigid bronchoscopy may
reduce need of opioids, shorten recovery time, prevent
respiratory acidosis, need for manually assisted ventilation,
reduce the oxygen need and allow optimal surgical condi-
tions [24, 25]. This author is aware that INPV is not com-
monly used in this condition, mainly due to lack of large
randomized controlled trials. Accordingly, a review such
this is important to disseminate experience and promote
research in this area.
Video-assisted thoracoscopic surgery is a minimally in-
vasive technique allowing for intrathoracic surgery with-
out any formal thoracotomy and related complications
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[26]. We successfully used face mask NIV with regional
anaesthesia during this technique which requires the ex-
clusion of a lung from ventilation [27].
High transmissible infections
There are still insufficient data on the use of NIV during
pulmonary infections, including pandemic respiratory
infections [28]. NIV was used in patients with Severe
Acute Respiratory Syndrome (SARS) in 2002–2003 and
also during the H1N1 epidemic in 2009. Thereafter NIV
has been used to treat ARF due to other infectious
diseases, like pandemic avian influenza (H5N1). However,
NIV in these conditions requires caution. Although stud-
ies of NIV use in ARF during H1N1 influenza [28, 29] do
not report disease transmission from patients to health-
care workers, the World Health Organization (WHO) has
included NIV among aerosol-generating procedures with
possible risk of pathogen transmission [30].
The members of an International NIV Network
examined the literature of NIV in SARS, H1N1 and
tuberculosis. The conclusion was that early application
of NIV in selected patients can reverse ARF. Further-
more there were only a few reports of infectious disease
transmission among healthcare workers [31].
Despite these positive results, the guidelines from the
European Respiratory Society (ERS)/European Society of
Intensive Care Medicine (ESICM), WHO, the UK Na-
tional Health Service, Hong Kong Lung Foundation and
the American Association for Respiratory Care (AARC),
suggest that NIV should not to be used as first-line ther-
apy in H1N1-associated ARF for several reasons: [32, 33]
1) Poor clinical efficacy in severe ARF rapidly progres-
sing to refractory hypoxaemia and ARDS; 2) More
prevalent hypoxaemic instead of hypercapnic ARF in pa-
tients with H1N1; 3) Concern about aerosol droplet par-
ticle dispersion and spread of infection.
Technical issues in ARF caused by airborne infec-
tious diseases include: 1) Ventilators with a double-
line circuit without an expiratory port (like whisper,
plateau exhalation valve, anti-rebreathing valve etc.)
should be preferred. This can reduce the risk of dis-
persion of exhaled infected particles through the
intentional leaks of a single line circuit; 2) Well cus-
tomized face masks should be preferred to nasal
masks to avoid the potential spreading of contami-
nated air particles from the mouth; 3) Healthcare
workers should be aware of the potential risks of
using NIV in such conditions taking appropriate pre-
cautions especially during the patient disconnection
from the NIV; [34] 4) In general, patient isolation
and protective measures also for care-givers should
limit if not avoid disease transmission; 5) The use of
other techniques such as high flow nasal cannula are
controversial.
Palliative and end-of-life care
Most end-stage patients with chronic respiratory failure
complain of dyspnoea in the last 3 months of life [35].
Breathlessness is often more severe in these patients than
in those with advanced lung cancer [36]. As a conse-
quence, NIV is being increasingly used to relieve dyspnea
in these patients [37, 38]. Recent guidelines state the
following: “As relief of dyspnoea with NIV may not relate
to changes in arterial blood gases, it is appropriate to
reassess the br0eathlessness experienced by patients
receiving such ventilatory support at frequent intervals”
[39]. Observational studies as well as clinical trials have
recently confirmed the role of NIV in patients with
chronic disease and poor life expectancy (with or without
COPD), showing that this ventilatory technique may
favourably reduce dyspnoea shortly after initiation, even
without an associated episode of hypercapnic ARF [40].
About half of the patients survived the episode of respira-
tory distress and were discharged from the hospital.
A Task Force of the Society of Critical Care Medicine
defined the approach to NIV use for end-stage patients
who choose to forego ETI [41]. The use of NIV for patients
with ARF could be classified into three categories: 1) NIV
as life support with no preset limitations on life sustaining
treatments; 2) NIV as life support when patients and fam-
ilies have decided to forego ETI; and 3) NIV as a palliative
measure when patients and families have chosen to forego
all life support, receiving comfort measures only. NIV
should be applied after careful discussion of the goals of
care, with explicit parameters for success and failure, by
experienced personnel and in appropriate healthcare set-
tings [41, 42]. The use of NIV in these circumstances
should take into account ethical, legal and religious issues.
Elective ventilation in respiratory failure - can you
prevent ICU care in patients with COPD? (Michael Dreher,
Michele Vitacca, Nicolino Ambrosino)
Key points
 Chronic respiratory failure is very frequently the
final stage of the natural history of chronic
obstructive pulmonary disease.
 The role of long-term non invasive positive pressure
ventilation in improving survival in COPD patients
with CRF is still discussed.
 Long-term night non invasive ventilation in these
patients has some physiological and clinical benefits.
 Long-term non invasive ventilation should be
reserved to individual patients.
Chronic respiratory failure (CRF) is very frequent in the
end stage of the natural history of chronic obstructive pul-
monary disease (COPD). Among other factors, inspiratory
muscle dysfunction due to pulmonary hyperinflation may
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lead to ineffective alveolar ventilation resulting in chronic
hypercapnia. Whether chronic hypercapnia is adversely
associated with overall prognosis is still discussed, at least
in patients on long term oxygen therapy (LTOT) [43].
Home long-term non-invasive positive pressure venti-
lation (NPPV) is widely used around Europe to treat
CRF due to different aetiologies such as restrictive thor-
acic (RTD) and neuromuscular disorders (NMD), obesity
hypoventilation syndrome and COPD [4].
The hypothesized - but not proven - mechanisms of
action of long-term NPPV in stable hypercapnic COPD
patients include: reverting hypoventilation; respiratory
muscle unloading; resetting of respiratory centers; and
cardiovascular effects. These mechanisms may work alone
or in combination.
Hypoventilation
Physiological studies demonstrate that in these patients,
NPPV is able to improve alveolar ventilation by increasing
the tidal volume and reducing the respiratory rate [44].
Respiratory muscles
Inspiratory support is able to unload the inspiratory mus-
cles, and positive end expiratory pressure (PEEP) counter-
acts the intrinsic PEEP associated with hyperinflation, [45]
an effect more evident in acute exacerbations.
Respiratory centers
Compared with LTOT alone, the addition of night NPPV
results in significant increases in day-time arterial oxy-
gen (PaO2) and reductions of carbon dioxide (PaCO2)
tension, total sleep time, sleep efficiency, and overnight
PaCO2. Additionally, health-related quality of life with
LTOT plus NPPV was significantly better than with
LTOT alone. The degree of improvement in day-time
PaCO2 correlates significantly with the improvement in
mean overnight PaCO2 [46].
Cardiovascular effects
Nighttime NPPV may improve heart rate variability, re-
duce circulating natriuretic peptide levels, and increase
the functional performance of patients with advanced
but stable COPD - suggesting that night NPPV may
reduce the impact of cardiac comorbidities in COPD
patients [47].
Clinical results
Although home NPPV is widely accepted for the treat-
ment of chronic hypercapnia due to respiratory or
neuromuscular disease, whether stable hypercapnic
COPD patients should routinely be offered this therapy
is still discussed [48]. Recently, the role of ventilator
management on physiological parameters and outcome
in stable hypercapnic COPD patients has become more
evident. It is suggested that its benefits depend on the
ability of NPPV to substantially reduce PaCO2 through
using “high” inflation pressures [49]. This was confirmed
by prospective trials, showing an advantage of high
over lower inspiratory pressure levels, with regard to
improvements of lung function, blood gases, exercise-
induced dyspnoea and health status [50, 51]. A multicen-
ter study showed a highly significant survival advantage
of NPPV (compared with standard care) when it was
targeted to maximize hypercapnia reduction [52]. The
findings of that study may influence the attitude of clini-
cians on the use of NPPV in patients with stable hyper-
capnic COPD. However, the effect of elective home
NPPV on exacerbation frequency in stable hypercapnic
COPD remains to be determined.
The use of NPPV is a first line treatment of acute on
chronic hypercapnic respiratory failure in COPD pa-
tients [8]. However, once acute hypercapnic respiratory
failure is successfully managed and these patients are
discharged, there is an 80 % re-hospitalization rate due
to another acute exacerbation over the following year
[53]. Furthermore, long-term survival in this patient
cohort remains poor [54]. Three relatively small studies
investigated the effect of home NPPV after acute hyper-
capnic respiratory failure successfully treated in COPD
patients. One study showed that, compared to sham
(continuous positive airway pressure) ventilation, NPPV
significantly reduced the probability of recurrent acute
hypercapnic respiratory failure [55]. Another study com-
pared home NPPV versus standard therapy in chronic
hypercapnic respiratory failure patients after acute ex-
acerbation in order to prevent clinical worsening [56].
The authors demonstrated that the probability of clinical
worsening was significantly lower in the group receiving
home NPPV, with additional improvements observed in
exercise capacity. The third, retrospective, study demon-
strated better survival in COPD patients discharged after
acute respiratory failure with home NPPV compared to
those discharged without this form of therapy [57].
Pro/Con long-term NPPV
There is limited evidence to support the provision of NPPV
in the home environment after successful treatment of
acute hypercapnic respiratory failure in COPD patients.
However, those studies supporting this intervention had
limitations, including small sample size, retrospective na-
ture, and a lack of control group. Struik et al. [58] evaluated
whether home NPPV after successfully treated acute
respiratory failure reduces re-hospitalization and improves
survival. The investigators randomized patients to home
NPPV or standard treatment 48 h after “acute” ventilator
support was terminated. The study failed to show a positive
effect of home NPPV on time to readmission or death. This
was not anticipated and stands in clear contrast to the
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smaller studies published before. Looking deeper into the
study it can be seen that both groups had reductions in
PaCO2 over time. Therefore, one explanation of why this
multicenter study was negative was the fact that patients
were randomized too early: given the natural course of the
disease, patients might have been randomized while they
were still recovering from acute hypercapnia. Therefore,
home NPPV might have been prescribed to patients not
suffering from chronic hypercapnia. This study under-
scores the importance of carefully selecting patients for
home NPPV.
Another study [59] was unable to show an improvement
in 2-year survival, despite the demonstration of reductions
in day-time PaCO2 (while breathing oxygen), improve-
ments in health status, and reductions in readmissions.
Therefore, it appears unlikely that differences in 1 year sur-
vival between the Köhnlein study [52] and others [58, 59]
are due only to “high inspiratory pressures” or simply re-
ductions in PaCO2 [52]. As a matter of fact, the control
group of the Köhnlein study suffered from a high mortality
rate, which may indicate that severity of disease rather than
the correction of hypercapnia or the beneficial effect of
“high inspiratory pressures” primarily drives survival in pa-
tients treated with NPPV. Furthermore, claim that chronic
hypercapnia is associated to worse survival is questionable
- at least in those patients receiving long-term oxygen
therapy [43]. Furthermore there is growing evidence that
mortality in COPD is influenced by several other factors,
such as exercise capacity, comorbidities and inflammatory
status [60].
Overall, home NPPV has been shown to improve import-
ant physiological parameters in stable hypercapnic COPD
patients by the use of a treatment strategy which sufficiently
decreases elevated PaCO2 levels [51]. By doing so, long
term survival can be significantly improved. However, the
influence of home NPPV to prevent re-hospitalization is
still unclear, and future trials are needed to identify the sub-
group of COPD patients which benefits most from home
NPPV. From a clinical point of view, it seems reasonable
that patients with acute hypercapnic respiratory failure
needing mechanical ventilation in hospital and suffering
from prolonged hypercapnia, the ones you can define as
acute on chronic hypercapnia respiratory failure, might
benefit most. However, inconclusive data are available up to
date and further investigation is needed in this area.
Conclusion
There is conflicting evidence regarding the effect of
NPPV on reducing health care utilization and mortality
in acute on chronic respiratory failure due to COPD.
We need to better assess when to initiate this therapy in
patients with hypercapnia in this setting. Once stable
hypercapnia is proven, NPPV may improve survival and
health status. Therefore, despite recent studies adding
some new data, the authors cannot recommend the
widespread use of this therapeutic intervention after an
episode of acute-on-chronic respiratory failure in COPD.
There is simply not enough evidence to support it.
Instead, this modality should be reserved for individual
cases, treated in specialized centers experienced with
NPPV for the treatment of stable hypercapnic COPD.
Weaning in long-term acute care hospitals in the United
States Hospitals (Martin Tobin, Amal Jubran)
The non-intuitive term “long-term acute care hospital
(LTACH)” is viewed as the antonym of short-term acute
care hospital (STACH). The term originates with Medicare
bureaucrats who define LTACH as an acute care hospital
with a mean length of stay of at least 25 days. Prolonged
ventilation has been variously defined, as greater than
2 days, 14 days or 29 days, and now is generally, but arbi-
trarily, defined as at least 21 consecutive days of mechanical
ventilation [61]. A number of different names has been
applied to facilities focused on weaning from prolonged
ventilation, including step-down units, respiratory intensive
care units, and intermediate care units, which are located
within a short-term acute care hospital, or a LTACH, which
commonly is a free-standing hospital [61].
Much of the driving force behind LTACHs relates to
money. Costs for ICU beds in the US have increased dra-
matically: by 30.4 % per day between 2000 and 2005 [62].
Costs for mechanical ventilation in the US are estimated at
$27 billion, representing 12 % of all hospital costs. Because
of the formula employed for payment by Medicare, the
diagnosis-related group (DRG) system, hospitals begin to
lose large amounts of money when length of stay exceeds
14 days. Transfer of patients out of an acute ICU to a step-
down unit or LTACH saves money on a per-day basis,
largely by lower nurse-to-patient ratios, and by increase in
the availability of ICU beds for more profitable cases such
as elective surgeries.
Although money is the dynamo behind the expansion
of LTACHs, it is also recognized that patients being
weaned from prolonged ventilation have different needs
than patients in acute ICUs. These patients require a
greater rehabilitative, as opposed to life-support, focus
and they may benefit from being transferred out of the
high technology environment of an ICU.
Given the colossal sums of money spent on caring for
patients requiring prolonged mechanical ventilation, it is
amazing that these patients have attracted minimal
attention from science-oriented investigators as opposed
to health economists. This review is focused on science
and on how best to wean patients receiving prolonged
ventilation rather than on the economics of ventilator
care.
Between 2000 and 2010, Jubran et al. conducted a ran-
domized controlled trial to determine whether the method
Ambrosino et al. Multidisciplinary Respiratory Medicine  (2015) 10:29 Page 10 of 21
selected for weaning influenced weaning duration in pa-
tients receiving prolonged ventilation [63]. The two arms
of the study consisted of pressure support and trials of un-
assisted breathing using an O2 delivery device connected
to a tracheostomy tube (a trach collar). The primary aim
of the study was to determine the length of time required
for weaning with pressure support versus trach collar. Pa-
tients were eligible for entry into the study if they had re-
ceived mechanical ventilation for at least 21 days. All
patients underwent a screening procedure, which consisted
of breathing unassisted through a trach collar for 5 days.
One hundred and sixty patients did not develop distress
during the five days and were considered to have been suc-
cessfully weaned and were not randomized. Three hundred
and sixteen patients developed respiratory distress during
the 5-day period and were judged to have failed the screen-
ing procedure and were randomized to wean with pressure
support or trach collar. Patients randomized to trach collar
were disconnected from the ventilator and allowed to
breathe through the tracheostomy. During the first day, the
patient was allowed to breathe unassisted for a maximum
of 12 h. The patient was then reconnected to the ventilator
and assist-control ventilation was instituted for the next
12 h. On the second day, the 12-h trach-collar challenge
followed by assist-control ventilation was repeated. On the
third day, the patient was disconnected from the ventilator
and allowed to breathe unassisted through the trach collar
up to 24 h. In the pressure-support arm, on the first day
the initial level was titrated to achieve a total respiratory
frequency of less than 30 breaths per minute. Attempts
were made to decrease pressure support by 2 cmH2O three
times each day. When a patient was able to tolerate pres-
sure support of no more than 6 cmH2O for at least 12 h,
the ventilator was disconnected and the patient allowed to
breathe unassisted through the tracheostomy up to a max-
imum of 24 h each day.
The primary outcome, weaning duration, defined from
the first day of randomization to the day the patient was
successfully weaned, was shorter with trach collar than
with pressure support: 15 versus 19 days. Patients were
considered weaning successes when they breathed without
ventilator assistance for at least 5 days. A Cox propor-
tional hazards model revealed that the rate of successful
weaning was 1.43 times faster with trach collar than with
pressure support. Mortality was equivalent in the two
arms, but, of course, the study was not powered to detect
a difference in mortality. Of the entire 500 randomized
and non-randomized patients, 54 % were alive at 6 months
after enrollment and 45 % were alive at 12 months. This
survival rate is surprisingly high. To put the numbers in
perspective, 1-year survival in older (66 years) patients
ventilated in an ICU was approximately 40 % [64, 65].
That is, the LTACH patients in the study of Jubran et al.,
who were ventilated for 67 days, had a 1-year mortality
comparable to ICU patients who were ventilated for
9 days. Indeed, 72 % of the 260 patients who had been
weaned by discharge were alive at 12 months.
What explains the faster pace of weaning with a trach
collar than with pressure support? One explanation lies
with how doctors make decisions. During a trach-collar
challenge, the amount of respiratory work is determined
solely by the patient – the ventilator cannot do any work.
As such, a physician observing a patient breathe through a
trach collar has a completely clear view of the patient's
respiratory capabilities. During pressure support weaning,
a clinician's ability to judge weanability is clouded because
the patient is receiving ventilator assistance and it is
extremely difficult to distinguish between how much work
the patient is doing and how much work the ventilator is
doing [66]. Accordingly, clinicians are more likely to accel-
erate the weaning process in patients who perform unex-
pectedly well during a trach-collar challenge than when a
low level of pressure support is being used. This notion is
borne out by the Kaplan-Meier plot, which shows that the
superiority of trach collar over pressure support was evi-
dent within the first ten days of the study [63].
In summary, the number of patients requiring prolonged
mechanical ventilation, whether they are placed in a short-
term acute care hospital or some other location, is likely to
increase enormously in the next few decades. The use of a
trach collar accelerates the pace of weaning of such patients
by more than 40 % as compared to weaning using pressure
support.
The difficult-to-wean patient: comprehensive management
(Guido Vagheggini, Nicolino Ambrosino)
Key points
 Prolonged weaning is defined as the need for more
than three weaning trial failures, or 7 days from the
first spontaneous breathing trial
 Specialized weaning units allow greater weaning
rate, better functional status
 Survivors may suffer from long-lasting physical and
cognitive disabilities resulting in impaired quality of
life
 Physiotherapy is part of the comprehensive
management
 Protocol-based weaning strategies may be effective
 High risk of dysphagia has been reported in critically
ill patients.
Prolonged weaning is defined as the need for more than
three weaning trial failures, or 7 days from the first spon-
taneous breathing trial [67]. It occurs in up to 14 % of
patients admitted to intensive care units (ICU) and treated
with invasive mechanical ventilation, accounting up to
37 % of ICU costs [68, 69]. These patients have a hospital
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mortality up to 32 %, [70] and fewer than half of them sur-
vive beyond 1 year [71]. Specialized weaning units allow
better results, in terms of percentage of patients free from
mechanical ventilation, and functional status at discharge,
particularly if the organizational model is focused to the
early post-acute period [72].
Clinical outcomes of critically ill patients admitted to
ICUs showed a huge improvement in the last decades,
due to the advancements in critical care. Nonetheless, sur-
vivors may suffer from long-lasting physical and cognitive
disabilities resulting in impaired quality of life, even after
long time from the acute illness [73].
It has been reported that muscle wasting in critic-
ally ill patients starts in the very first week of illness
being more severe in patients with multiorgan failure
than in those with a single organ failure [74]. Physio-
therapy must be considered as an integral part of the
comprehensive management of these critically ill pa-
tients. A strategy of early comprehensive rehabilita-
tion based on interruption of sedation and physical
and occupational therapy is safe and well tolerated,
resulting in better functional outcomes at hospital
discharge, shorter delirium, and more ventilator-free
days [75]. Current guidelines and recommendations
promote early mobilization in ICU, to reduce decon-
ditioning and other immobility related complications,
and increase functional independence and psycho-
logical well being [76]. Neuromuscular electrical
stimulation (NMES), able to exercise muscles with
minor burden on cardio-ventilatory system, can be
easily performed in the ICU and applied to muscles
of patients laying in bed to prevent the ICU neuro-
myopathy [77].
Despite no definitive results exist regarding the applica-
tion of a fixed protocol-based procedure to discontinue
mechanical ventilation, the use of this care plane has
proven to be effective when applied to the weaning
process in the critical care area [78]. Recent advances in
mechanical ventilation (NAVA, closed loop) were devel-
oped to facilitate weaning in acute care and in prolonged
weaning [79]. Some recent meta-analysis [80] showed that
weaning with closed-loop ventilators significantly de-
creased weaning time in critically ill patients, however, its
utility when compared with respiratory physiotherapist
protocolized weaning is still a matter of debate [81].
Aside from regaining respiratory autonomy and clinical
stability, the removal of tracheotomy may represent a diffi-
cult challenge in prolonged weaning patients, and
currently available recommendations are still largely based
on subjective criteria rather than on standardized proto-
cols. High risk of dysphagia has been reported in critically
ill patients, and an accurate evaluation of swallowing
disorders may reduce risk of infections and failure of
tracheostomy weaning [82].
Telemonitoring in ventilator dependent patients (Michele
Vitacca)
Key points
 Home mechanical ventilators may be equipped with
remote monitoring tools in order to improve physician
supervision, with the aim to adapt settings to the
needs and comfort of the patient
 Economic, regulatory and legal impacts of home
telemonitoring will be important in its adaption by
health care systems
 Relevant issues are prescription criteria, modalities of
follow-up, team expertise, technologies, adherence,
bundling of services, and outcomes
Introduction and rationale
Patients with chronic respiratory insufficiency requiring
home mechanical ventilation (HMV) have a high, although
underestimated prevalence in Europe [4]. Home mechan-
ical ventilation requires patient and family cooperation,
nevertheless clinical conditions, technology needs, lack of
professional supervision, and acute exacerbations make its
management a difficult task [4, 83]. Provision and mainten-
ance is often carried out by external companies, without
any accepted standardisation, and a regular feedback to the
clinical centres is usually lacking [84]. The need to reduce
healthcare costs has prompted the development of tele-
medicine for home assistance [85]. However, only few con-
trolled studies evaluating its effectiveness are available so
far. Identification and selection of HMV patients who may
benefit from such tele-monitoring approach represent key
factors [86]. There are real challenges when providing
HMV, including patient and caregiver training, adequacy of
respiratory care, and reimbursement.
The aim of a recent ERS Task Force has been to develop
and establish a European network of clinical experts in
HMV for a critical analysis of the current status of tele-
monitoring services in ventilator-dependent patients and
provide a consensus document on common clinical criteria,
equipment, and facilities.
Overview on telemedicine, telemonitoring definitions
Telemedicine (TM) is the distribution of health services -
in conditions where distance is a critical factor - by health
care providers using information and communication
technologies to facilitate the exchange of important clin-
ical information [86]. TM dimensions may be divided into
functionality, applications and technology categories.
Functionality, in turn, may be divided into:
a) Tele-consultation: Second opinion on demand
between patient/family and staff or among health
operators; opinions, advice provided at distance
between two or more parties separated geographically
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b) Decision support system: Alerting health personnel,
in response to a sentinel value, who then contact the
patient or caregivers
c) Remote diagnosis: Identifying a disease by the
assessment of the data transmitted to the receiving
party through instrumentation monitoring a patient
away.
d) Tele-therapy: Direct prescription
e) Mentoring (i.e., tele-coaching): Direct reinforcement
or recorded messages/communications to improve
adherence
f ) Telemonitoring: Digital/broadband/satellite/wireless
or bluetooth transmission of physiologic and other
non-invasive data (i.e. biological storage data
transfer)
g) Tele-evaluation: On-demand data transfer to use as
biological outcome measures
h) Telecare: Network of health and social services in a
specific area; in case of emergency, patient calls
medical personnel, emergency call service or
members of family
i) Telerehabilitation: The system which allows for
receiving home care and guidance on the process of
rehabilitation through connections for point-to-
point video conferencing between a central control
unit and a patient at home.
j) Emergency calls: Helpline service that gives the
ability to initiate a call for help to an Operation
Centre, usually active 24 h a day throughout the
year
k) Teleconference-Audio: Electronic two-way voice
communication between two or more people located
in different places, which make use of transmission
systems voice, video and/or data.
l) Telepresence: Use of robotic devices and other
devices allowing to perform a task in a remote place
by manipulating instruments and receiving sensory
information and reactions.
m)Telespirometry: Remote control of a flow volume
curve through a spirometer which is then sent to a
central processing and reporting
Indications for TM in ventilator-dependent patients
In general, TM would be appropriate in patients receiv-
ing supported ventilation outside an acute care hospital,
including those receiving non invasive ventilation (NIV)
and those receiving invasive ventilation (IV). The latter
would include those with as weaning failure and those
undergoing some kind of a weaning process.
Telemonitoring could be used for:
Ventilator Weaning: As an adjunct to weaning outside
the acute care hospital [87].
ALS (amyotrophic lateral sclerosis) [87–89]: TM in venti-
lated patients due to ALS has been addressed in the
medical literature. One study by De Almeida and colleagues
demonstrated that the device was user-friendly [89]. A pro-
spective, single blinded, controlled trial of TM versus no
TM in 40 ALS showed that telemonitoring reduced health
care utilization and probably had beneficial effects on
survival and functional status [87]. TM is cost-effective in
these patients representing major cost savings to the NHS
in the order of 700 euros/patient/year.
Chronic respiratory failure [90–100]: In general, TM for
chronic respiratory failure is feasible, tends to reduce hospi-
talisations, relapses, and urgent GP calls, helps facilitate
titration of oxygen, and helps with changes in mechanical
ventilation settings.
Equipment/technology available
The components of the technological dimension can be
grouped into three sets, of variables: synchronicity, network
design, and connectivity [85]:
a) Synchronicity is used here to incorporate both
timing and technology.
b) Network design/configuration includes three
modalities: Virtual Private Networks, the open
internet, and social networks, in which information
is posted and shared.
c) Connectivity, wired and wireless, provides different
levels of bandwidth and the attendant speed and
resolution or quality of service.
A wide range of remote health monitoring systems is
available. The correct level of technology should be: i) safe;
ii) feasible; iii) effective; iv) sustainable; v) and flexible to
meet different patient’s conditions and needs.
Time of TM follow up
Tele-monitoring has been proposed for home use, with
a proposed time of use ranging from 3 months to 4 years
[87, 89, 90, 101–106].
Legal issues
The use of TM has highlighted several medico-legal issues
that must be addressed as this intervention achieves greater
acceptance [107]. Further governmental, ethical, legal, regu-
latory, technical, and administrative standards for remote
medicine will be necessary to assist individuals and organi-
zations in providing safe and effective services.
Economical considerations
As awareness of the potential role of at-home telecare and
telemonitoring in the care of ventilator-dependent (VD)
patients increases, potential roadblocks also become more
apparent. This type of care is labor-intensive and costly,
[107] and the current medical literature on its cost/effect-
iveness presents contrasting results [89, 95, 100, 104].
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Analyses comparing institutional versus at-home inter-
ventions in VD patients focused on traditional outcomes
such as hospitalization rates. This narrow approach ignored
such important methodologies and outcome areas as:
a) Telemonitoring vs. formal caregiver monitoring in at
home VD patients’ care, in order to potential savings
of telemonitoring compared to high intensity labor
home activities;
b) Quality of life comparison between the above two
groups.
To evaluate the real cost/effectiveness of a new method
such as remote monitoring in this population, it is import-
ant to understand what “standard therapy” and “usual
therapy” actually refer to in published papers. Often the
comparator treatment is quite variable among European
countries. “Standard therapy” can be considered to en-
compass the drug prescription, control by the general
practitioner (GP), structured outpatient programs, and
pathways of integrated on-demand home visits with dedi-
cated paths in highly disabled patients. Each of these pro-
grams may have different indications, applicability and
costs, making generalizations from comparison s with a
new protocol of remote monitoring problematic. Despite
preliminary studies that have shown an advantage in
applying telehealth systems, more recent research casts
some doubts on their superiority with regard to effective-
ness or cost savings.
Tele-rehabilitation for home mechanical ventilated patients
Integrating telehealth into existing health service delivery
patterns will require a reliable technological infrastructure,
effective clinical demonstrations, assessment of practi-
tioners' readiness, and careful integration of technologies
into workflow and policy synchronization. Future initiatives
will cover developing organizational models, promoting
sustainability and participation, creating feasible, econom-
ical, effective and safe technological models, developing
new technical devices and software and – ultimately - dem-
onstrating effectiveness at the clinical level (including cost
reduction, enhancement of quality of life, and patient/care-
giver support).
Role of telemedicine in sleep-related breathing disorders
Sleep-related breathing disorders (SRDB) are a group of
pathologies characterized by abnormalities of the respira-
tory pattern during sleep. The two most important are
obstructive sleep apnea (OSA) and the reduction of ventila-
tion during the night (hypoventilation syndromes). Recent
investigations have evaluated the application of telemedi-
cine in the diagnosis, treatment and compliance in OSA
patients. For hypoventilation syndromes, the following
areas should be considered in investigations. a) Indications
for treatment; b) NIV titration; c) Optimal NIV devices and
quality control; d) Follow-up strategies; e) Procedures to
obtain adequate ventilation; and f) Treatment adherence.
Finally, cost-effectiveness must ultimately be addressed.
Telemedicine at the end of life
Telehospice, the use of telemedicine technologies to pro-
vide services to hospice patients [108–110], may offer an
innovative solution to the challenges of providing high-
quality, cost-effective end-of-life care.
Future considerations
Tele-monitoring could become be a key element (part of
the ‘total package’) in the integrated management of the pa-
tient requiring home mechanical ventilation for chronic re-
spiratory failure. Future outcome assessment could include:
1. Physiological and functional impact: Impact of home
mechanical ventilation on physiologic and functional
status variables.
2. Survival and quality of life: Outcomes related to
quantity and quality of life; including daily living
activities, social interactions, autonomy, self-
management, etc.
3. Health services: Use of health services directly
related to home mechanical ventilation: phone calls,
technical home visits.
4. Resources use: Use of health services (emergency
visits, admissions, out-patient visits…) and, specially,
the caregiver burden.
Ethics and palliative care in critically-ill respiratory
patients (Michele Vitacca)
Key points
 The trajectory of the dying process in COPD
patients is highly variable
 Lack of surveillance and inadequate services with
absence of palliative care is a routinely experience.
 Patients with COPD most frequently request
information on the diagnosis and disease process, its
treatments, prognosis, maintaining quality of life,
and advance care planning.
 All too often, palliative home care programs and
hospice admissions for end of life care in respiratory
patients are insufficient or absent.
In the USA, non-oncological respiratory causes account
for 8 % of all deaths and 9.6 % of deaths in individuals over
age 65 years; of these 56 % are from COPD [111]. The
COPD time course is characterized by a progressive wors-
ening of dyspnoea, reduced effort tolerance, and more
frequent exacerbations and hospitalizations [36]. In COPD,
oxygen therapy and mechanical ventilation (MV) improve
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survival and morbidity in acute-on-chronic respiratory fail-
ure [36]. The downhill trajectory in COPD patients is vari-
able and not as predictable as that of other chronic diseases
[36]. In general, the course of COPD is that of progressive
long-term disability, with periodic exacerbations and unpre-
dictable timing of death which characterize dying with
chronic multiorgan failure [36]. In a provocative paper,
Curtis et al. [36] proposed that, after a serious analysis of
the conditions and clinical status, we would define a
patient needing palliative care when he/she has a low
chance of recovery, poor rehabilitation potential, and high
organizational complexity and instrumental requirements.
Multiple factors influence quality of care for COPD
patients requiring palliative care. Three examples in-
clude: 1) the presence of anxiety and depression, which
are as common in advanced COPD; 2) the use of ad-
vance care planning; and 3) effective communication
among the patient, family and health care providers.
Those individuals in their last days of life (typically, an
estimated of death within the next 7 days) may be defined
as end of life (EOL) patients. Caring for these patients
should be defined as potentially "futile", i.e. disproportion-
ate measures in terms of quality and quantity of care with
poor expected quality of life.
The hospital is often the location where EOL decisions
are made for patients with end-stage COPD [112]. The
patient, family and health care providers are usually in-
volved in this process; all provide different perspectives and
expectations. In a recent survey Nava et al. [113] showed
that, in European respiratory intermediate care units and
high dependency units, an EOL decision was made in
21.5 % of patients. Withholding of treatment, do-not-
intubate/do-not-resuscitate orders, and noninvasive mech-
anical ventilation (NMV) as the ventilatory care ceiling are
the most common forms of decision-making. In the same
survey, the investigators showed that competent patients,
together with nurses, are often major players in EOL deci-
sions. A common notion is that European intensive care
unit (ICU) physicians, in most cases, do not experience
difficulties with EOL decisions. However, Sprung et al.
[114] underline that EOL decisions change according to
diagnosis, countries and doctors’ religion. Another import-
ant point is the well-known difficulty in accurately predict-
ing outcomes (including death) for COPD patients
admitted the ICU.
Wildman and colleagues [115] investigated whether
clinicians' prognoses matched survival outcome in pa-
tients hospitalized in 92 ICU and three respiratory
high-dependency units in the United Kingdom with
severe acute exacerbations of COPD. Of this group,
517 (62 %) survived out to 180 days. In general, the
clinicians' prognoses were too pessimistic: their pre-
dicted survival was 49 %. Furthermore, for their pa-
tients with what they considered the severest disease,
predicted survival was 10 %, but in reality it was
40 %.
Gerstel at al. [116] pointed out that one of the main
problems is that withdrawal of life support in the ICU is
often a complex process, influenced strongly by patient
and family characteristics. In this study, in almost one-half
of the group, the decision to withdraw life-sustaining ther-
apy took longer than one day. Those patients with longer
decision-making were younger, had a longer length of stay
in the ICU, received more life-sustaining interventions,
were less likely to have a diagnosis of cancer, and had
more decision-makers involved in the process. A longer
decision process leading to withdrawal of life support was
associated with increased family satisfaction, as was extu-
bation before death.
As compared to hospitalized patients with lung cancer,
individuals with COPD were more likely to receive mech-
anical ventilation, tube feeding, and resuscitation [117].
Furthermore, in COPD patients, mechanical ventilation
had greater short term effectiveness, based on survival to
hospital discharge (76 % vs. 38 %), and had higher 2-month
and 6-month survival. Curtis and colleagues [118] pointed
out an additional important problem related to EOL is the
strategy of communication: the physicians’ frequent difficul-
ties in discussing EOL care with patients and their families
and caregivers
Health care utilization is strongly weighted toward the
end of life in COPD as well as in other diseases. For ex-
ample, Andersson and colleagues [119] showed that more
than 68 % of all COPD admissions and 74 % of all days in
hospital occurred in the 3.5 years before death. The last
6 months of life accounted for 22 % and 28 % of all COPD
admissions and days, respectively. Suboptimal surveillance,
inadequate services, and absence of palliative home care are
common in severe COPD patients with EOL issues [120].
This also holds for respiratory patients who are house-
bound with high levels of morbidity and high requirements
for community health services. COPD patients approaching
EOL require, at a minimum, education on diagnosis and
disease process, available treatment modalities, what they
have to do and what to expect, and information on progno-
sis. Despite this, only 32 % of respiratory patients report
discussing EOL cares with their physicians [120]. Stated
barriers in this study included, “I would rather concentrate
on staying alive than talk about death” or “I’m not sure
which doctor will be taking care of me if I get very sick.”
Thus, it is necessary to identify areas of communication
that physicians do not address and areas that patients rate
poorly, including talking about prognosis, dying and
spirituality.
Finally, issues in COPD patients with mechanical venti-
lation (MV) deserve mention. Marchese et al. [121] de-
scribe survival, predictors of long-term outcome and
attitudes in patients treated at home by tracheostomy-
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intermittent positive-pressure ventilation (TIPPV) over a
10-year period. Sixty-four out of 77 patients (83 %) were
pleased to have chosen MV with tracheostomy and 69
(90 %) would choose this option again. Forty-two care-
givers (55 %) were pleased the patients had chosen home
mechanical ventilation (HMV), but 29 (38 %) reported
major burdens. TIPPV is generally well-received by pa-
tients, is considered safe, and often permits survival for
relatively long periods of time.
Vitacca et al. [35] describe the family’s perception of care
delivered to home MV patients during the last 3 months of
life. Eleven Respiratory Units submitted a binary 35-item
questionnaire with 6 domains (symptoms, awareness of dis-
ease, family burden, dying, medical troubles and technical
problems) to close relatives of 168 deceased patients (41 %
with COPD). The majority had prominent respiratory
symptoms and were aware of the severity and prognosis of
their disease. Family burden was high, especially with re-
spect to financial burden. During hospitalisation, 74.4 % of
patients had been admitted to an ICU and 27 % received
resuscitation manoeuvres. Hospitalisations and family fi-
nancial burden were unrelated to diagnosis and use of MV,
and families of the patients did not report major technical
problems regarding the use of ventilators [35]. Steele et al.
[122] describe how hospice care can offer expertise for pal-
liation and may be used as a bridge between hospital and
home.
Communication with patients and families about EOL
issues is an important component of proper medical care
that is often neglected in the training of clinicians. Al-
though direct studies of health care provider interaction in
COPD in this setting are not readily available, Vitacca et al.
[123] showed how to communicate bad news to caregivers
of patients with amyotrophic lateral sclerosis (ALS). In
particular, caregivers require major assistance during the
delicate times of discussing advance care planning and
directives and critical treatments decisions. Clinicians are,
therefore, an important target group for education on this
type of communication. The Calgary–Cambridge model
for medical consultations and the SPIKES (Setting up, Per-
ception, Invitation, Knowledge, Emotions, Strategy and
Summary) [124] for breaking “bad news” provides exam-
ples of consultation guides that integrate patient agenda
with biomedical issues. Communication of advance care
planning, defined as an ongoing discussion among pa-
tients and family members may be a more effective mean
to meet patients' wishes.
Future direction for non-oncological respiratory patients
with severe disease or EOL issues will focus on outcomes
as well as skills and interventions for doctors, nurses and
respiratory therapists. Many questions remain unanswered:
Which are the important, measurable prognostic indica-
tors? Which are indicators for unmet patient and caregiver
needs? Which interventions optimize quality of life in this
setting? Which are the important, relevant and priority
criteria for palliative network and hospice access? What are
the economic and social costs? What about enterable nutri-
tion withdrawing? What about bio-ethical issues? What
about patient information as awareness and self decision?
In conclusion, for respiratory patients with EOL issues
we need to:
 Offer the best practice to ameliorate the pervasive
effects of the disease
 Recognition that medication alone is insufficient to
achieve optimal outcome
 Control the often overwhelming symptoms (such as
dyspnoea) and psychological symptoms
 Focus our care on our patient and the family
 Allow for and foster a continuous presence of
family, friends and religious assistance
 Give time and place to our patient to say everyone
“good bye”
 Talk to our patients and relatives using their
language
 Listen to our patients and their families and
caregivers
 Consider patients’ preferences
 Not unduly prolong suffering to maintain life in
some EOL situations
 Consider hospice and “palliative care” as
opportunities for our patients
Ethics and palliative care in ventilator dependent patients
(Guido Vagheggini, Nicolino Ambrosino)
Key points
 The care of end-stage patients requires a progressive
reduction of useless and “futile” treatments and an
increasing approach to relieve of symptoms
 Clinicians are involved in surrogate or joint decision
making
 Patient centered supportive care should respect
patients’ values and preferences
 Physicians and healthcare professionals are
challenged by prognostic accuracy of patient
survival.
 End-stage COPD patients receive far less opiates
than cancer subjects to alleviate dyspnea.
The care of end-stage patients requires a progressive
reduction of useless and “futile” treatments and an in-
creasing approach aimed to prevention and relieve of
symptoms, including maintenance and improvement of
quality of life of patients and families. Nevertheless end-
stage lung diseases like Chronic Obstructive Pulmonary
Disease (COPD) have a similar severe prognosis as lung
cancer, but lower risk of Intensive Care Unit (ICU)
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admission refusal compared to cancer or haematological
malignancies patients [125, 126].
Due to the different evolution of end stage chronic
respiratory diseases, and to the lack of physician’s accur-
acy in judgment of prognosis in terminally ill patients, it
may often be difficult to decide when to start palliative
treatment [36, 127]. In these patients, the transition
from the usual to the palliative and end of life care can-
not be a step down, but should start simultaneously to
the care, as soon as needed, and last until and after the
death to ensure appropriate support to the family.
In these patients the main questions a clinician should
face are: What might be desirable in terms of medical
intervention? Should we pursue aggressive treatment or
comfort treatment alone? In these patients, determining
whether a patient is dying or not has become as import-
ant as the management of organ support therapy itself,
as withdrawal or withholding of artificial life support
may be determinant for their survival [128]. Very often
clinicians are involved in surrogate or joint decision
making, even in major medical decisions, so they need
to be in partnership and communicating with surrogate
decisions makers [129].
Patient centered supportive care should respect pa-
tients’ values and preferences, be coordinated and inte-
grated in the care programme, and include an adequate
information, communication and education. Physical
comfort and emotional support of the patient should be
pursued, with the involvement of family and friends, in
order to share decisions and avoid abandonment experi-
ences when care is redirected toward a more palliative
purpose [130].
Physicians and healthcare professionals are challenged
by prognostic accuracy of patient survival in patients
with severe end-stage of COPD, and they are less likely
to engage in end-of-life care planning in contrast with
terminal diseases like cancer [131]. Home mechanical
ventilation (HMV) is a growing issue in developed west-
ern countries; it is often administered as a life-sustaining
treatment, but may have an important role also as a pal-
liative treatment of dyspnea [4, 132, 133].
More recent guidelines include the use of pharmaco-
logical treatment of dyspnoea. Nevertheless, despite the
beneficial response and the safety of opiates in end stage
lung disease has been demonstrated, the end-stage COPD
patients receive far less opiates than cancer subjects to
alleviate dyspnea [134–136]. Conversely, end- stage COPD
patients undergo more hospital and ICU admissions than
cancer patients, an evidence that some issues in general
and medical culture prevent appropriate supportive and
palliative care in non-cancer end-stage lung disease [137].
Also in amyothrophic lateral sclerosis (ALS) patients, a
high rate of hospital death is reported, the place of death
depending widely on the attitude of the hospital and
resources availability of the environment, more than on
patient’s and families’ preferences [138].
In conclusion, in the care of end-stage lung disease
patients, we must facilitate care in accordance with patient’s
wishes, when possible, by exploring advance directives and
involving family and care team in the development of the
management plan. Continued and intensive efforts have to
be addressed to palliate symptoms as earlier as possible
during the clinical course of the illness, simultaneously to
the care of treatable conditions, and recognizing the need
of end-of-life care when appropriate.
In this perspective, harmonising acute care criteria for
admission to ICU and criteria for long-term care is a
crucial challenge to make more ethical the care provided
to the patient.
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